Gina Mauro


Verzenio Continues to Show Reduced Risk in Invasive Disease-Free Survival in High-Risk Early HR+ Breast Cancer

December 11, 2020

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.